The Hindu Newspaper Group, in association with Hitachi Ltd., Tokyo (Japan) is offering Scholarships for technical training in Japan. The selected candidates for the scholarships will be trained in Hitachi company, Japan. The total number of scholarships are 3 (Three only). Applicants should not have completed 30 years of age as on 31-03-2012. Candidates should have B.E.,/ B.Tech or B.Sc. (Engineering) or its equivalent degree from any recognised University. Candidates with relevant industry experience will be preferred. Duration of the scholarships is six months. Following are details of training, scholarships and application procedure:

Trainees will have general training in the following areas: Industrial, Transportation and Urban Development Systems, Information and Telecommunication systems and Power Systems. Applications should be made in duplicate in the forms available on payment of Rs.5 from the offices of The Hindu mentioned below:

1. Kolkatta : LMJ Chambers, I Floor, 15C, Hemanta Basu Sarani, Kolkata – 700 001.
2. Chennai : 859 and 860, Anna Salai, Chennai – 600 002, or the Branch Offices at New Delhi : 3rd Floor, PTI Building, 4, Parliament Street, New Delhi- 110 001.
3. Coimbatore : 19 & 20, A.T.T. Colony, L.I.C Road, Coimbatore – 641 018.
4. Mumbai : Kasturi Buildings, Jamshedji Tata Road, Mumbai – 400 020.
5. Tiruchirapalli : Chennai Bye-Pass Road (NH 45), Senthanneerpuram, Tiruchirapalli – 620 004.
6. Madurai : 147/2A, Eighty Feet Road, K.K. Nagar, Madurai – 625 020.
7. Hyderabad : 6-3-879, & 879B, Begumpet Public Road, Hyderabad – 500 016.
8. Puducherry : 135, I floor, Mission Street, Puducherry – 605 001.
9. Visakhapatnam : 50-19-9, T.P.T Colony, Seethammadhara, Visakhapatnam – 530 013.
10. Bangalore: 19 & 21, Bhagwan Mahaveer Road, (Infantry Road), Bangalore – 560 001.
11. Vijayawada : 55-1-4, 100 Feet Road, Industrial Estate, Auto Nagar, Vijayawada – 520 007.
12. Kochi : NH Bye-Pass Road, Vytilla Junction, Kochi – 682 019.
13. Mangalore : 23-9-655/1, Jeppu, Mangalore -575001.
14. Thiruvananthapuram : T.C. No. 36/1946(1) ,` Airport Road, Vallakadavu, Thiruvananthapuram – 695 008.

Completed application forms should reach The Hindu, 859 and 860, Anna Salai, Chennai – 600002. Applications should be superscribed with ‘The Hindu – Hitachi Training Scheme’. Last date for submission of completed applications is 31st December 2011.

Sri Ramachandra University (Chennai), Tamilnadu is offering an innovative PG Diploma course in Translational Clinical Research. The trend of studying diseases at a molecular or cellular level and later progressing towards clinical level is fast gaining popularity across the science research community. Regenerative medicine will help in creating living, functional tissues to repair organ function. But it is a long process that needs quality and dedicated research and application skills along with well trained professionals. The PG Diploma in Translational Clinical Research offered by Sri Ramachandra University is a much relevant course in this regard. Following are details of the programme:

Eligibility and Qualification: Candidates with a Bachelor in Medicine or a Bachelor in Dental Science are eligible for the course (MBBS or Bachelor s in Science). Duration of the programme is one year; Course fee is Rs 60,000 approximately. Those completed the course will get an approximate starting salary of Rs 15,000- 25,000 per month and depends on the company. For more details about admission into this programme, see www.sriramachandra.edu.in.

The PG Diploma course has been developed in partnership with the international pharmaceutical company, Bristol-Myers-Squibb. The programme will be offered as an interdisciplinary training based course with an internship program for the students at the reputed Biocon- Bristol-Myers-Squibb Research Centre located at Bangalore. This course is intended to train the candidates to become industry-ready manpower for joining hospitals, research centers and pharma industries that involves in the conduct of clinical trials and pre- clinical toxicology work for drug development.